{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T23:31:43Z","timestamp":1782603103285,"version":"3.54.5"},"reference-count":45,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2008,6,1]],"date-time":"2008-06-01T00:00:00Z","timestamp":1212278400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatric Transplantation"],"published-print":{"date-parts":[[2009,2]]},"abstract":"<jats:p><jats:bold>Abstract:\u2002<\/jats:bold> PTLD is a severe complication in transplant recipients. Detection of increased EBV load in the peripheral blood acts as a surrogate marker for increased risk of PTLD development. We analyzed the time course of the disease, its severitiy, the organs involved, and mortality rates in our institutional experience of pediatric heart transplantation. This paper identifies risk factors for PTLD and describes the different ways of diagnosing and treating the disease. PTLD was screened for in 146 pediatric heart transplant patients using a retrospective analysis in patients who received transplantation before 1998. Prospective determination was performed in 72\/146 patients transplanted after 1998 within the post\u2010transplant follow\u2010up. The occurrence of PTLD with all interventions, including tapering of immunosuppression, surgery, viral monitoring, and antiviral interventions, was recorded. PTLD was diagnosed in 12\/147 (8.2%) children at a mean age of 7.2\u2003\u00b1\u20033.3\u2003yr after a mean post\u2010transplant period of 3.2\u2003\u00b1\u20032.2\u2003yr. PTLD manifested in: lymph nodes (n\u2003=\u20034), intestine (n\u2003=\u20033), tonsils and adenoids (n\u2003=\u20032), eye (n\u2003=\u20032), and lung (n\u2003=\u20031). It was diagnosed in 7\/12 as a monomorphic B\u2010cell lymphoma and in four patients as a monomorphic Burkitt lymphoma, a polymorphic B\u2010cell lymphoma, a T\u2010cell rich or angiocentric lymphoma (Liebow) and as reactive plasmacytic hyperplasia (early lesion), respectively. Histology was not possible in one patient with ocular manifestation. EBV association was 83%. Risk factors in the comparison with patients without PTLD were age at time of Tx, primary EBV infection after Tx, use of Azathioprine and \u22653 doses of ATG. CMV mismatch and CMV infection, rejection episodes and steroids were not risk factors. Despite reduction of immunosuppression, treatment consisted of surgical procedures to remove tumor masses (n\u2003=\u20036), Rituximab (n\u2003=\u20035), polychemotherapy (n\u2003=\u20033), antiviral (n\u2003=\u20031) and autologous T\u2010cell therapy (n\u2003=\u20031). All patients demonstrated full remission without death related to PTLD or treatment at 3.9 (1.3\u20136.2)\u2003yr median follow\u2010up time. The manifestation of PTLD in pediatric heart transplant recipients is associated with EBV infection and is predominantly in the form of a B\u2010cell lymphoma. A tight and specific follow\u2010up including early assessment of immunity status and specific therapeutic intervention to improve cellular immunity is warranted and may contribute to a significant reduction of PTLD\u2010related morbidity and mortality.<\/jats:p>","DOI":"10.1111\/j.1399-3046.2008.00969.x","type":"journal-article","created":{"date-parts":[[2008,6,2]],"date-time":"2008-06-02T04:04:26Z","timestamp":1212379466000},"page":"54-62","source":"Crossref","is-referenced-by-count":58,"title":["Diagnosis and treatment of post\u2010transplantation lymphoproliferative disorder in pediatric heart transplant patients"],"prefix":"10.1111","volume":"13","author":[{"given":"S.","family":"Schubert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Abdul\u2010Khaliq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. B.","family":"Lehmkuhl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Yegitbasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Reinke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Kebelmann\u2010Betzig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Hauptmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"Gross\u2010Wieltsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Hetzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,1,6]]},"reference":[{"key":"e_1_2_9_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-3046.2005.00401.x"},{"key":"e_1_2_9_3_2","first-page":"139","article-title":"Posttransplantation lymphoproliferative disorders (PTLD): Current perspectives","volume":"8","author":"Nalesnik MA","year":"1996","journal-title":"Semin Thorac Cardiovasc Surg"},{"key":"e_1_2_9_4_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.161.4.9901013"},{"key":"e_1_2_9_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1053-2498(02)01229-9"},{"key":"e_1_2_9_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-003-1392-x"},{"key":"e_1_2_9_7_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199810150-00007"},{"key":"e_1_2_9_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-0012.2006.00519.x"},{"key":"e_1_2_9_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2005.09.011"},{"key":"e_1_2_9_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2004.04.011"},{"key":"e_1_2_9_11_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199904150-00010"},{"key":"e_1_2_9_12_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-56352-2_2"},{"key":"e_1_2_9_13_2","first-page":"8","article-title":"Posttransplant lymphoproliferative disorders: Summary of Society for Hematopathology Workshop","volume":"14","author":"Harris NL","year":"1997","journal-title":"Semin Diagn Pathol"},{"key":"e_1_2_9_14_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-3062.2001.003002088.x"},{"key":"e_1_2_9_15_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.6.2052"},{"key":"e_1_2_9_16_2","first-page":"223","article-title":"Quantitative PCR in EBV\u2010infected renal transplant patients","volume":"24","author":"Merlino C","year":"2001","journal-title":"New Microbiol"},{"key":"e_1_2_9_17_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.5.1165"},{"key":"e_1_2_9_18_2","first-page":"1161","article-title":"Incidence and outcome of primary Epstein\u2013Barr virus infection and lymphoproliferative disease in pediatric heart transplant recipients","volume":"17","author":"Zangwill SD","year":"1998","journal-title":"J Heart Lung Transplant"},{"key":"e_1_2_9_19_2","first-page":"33","article-title":"Clinicopathologic features of posttransplant lymphoproliferative disorders","volume":"2","author":"Nalesnik MA","year":"1997","journal-title":"Ann Transplant"},{"key":"e_1_2_9_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2007.09.027"},{"key":"e_1_2_9_21_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00202391"},{"key":"e_1_2_9_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-9071(199811)56:3<186::AID-JMV2>3.0.CO;2-3"},{"key":"e_1_2_9_23_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.tp.0000179639.98338.39"},{"key":"e_1_2_9_24_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.TP.0000085602.22498.CF"},{"key":"e_1_2_9_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/sim.4780131603"},{"key":"e_1_2_9_26_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.TP.0000144333.19106.58"},{"key":"e_1_2_9_27_2","doi-asserted-by":"publisher","DOI":"10.1177\/107424840601100107"},{"key":"e_1_2_9_28_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-3046.2005.00318.x"},{"key":"e_1_2_9_29_2","doi-asserted-by":"publisher","DOI":"10.1086\/514142"},{"key":"e_1_2_9_30_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2006-926690"},{"key":"e_1_2_9_31_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02698031"},{"key":"e_1_2_9_32_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1K175"},{"key":"e_1_2_9_33_2","doi-asserted-by":"publisher","DOI":"10.1038\/labinvest.3700494"},{"key":"e_1_2_9_34_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2006.01540.x"},{"key":"e_1_2_9_35_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-3046.2003.00031.x"},{"key":"e_1_2_9_36_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-3046.2005.00361.x"},{"key":"e_1_2_9_37_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.TP.0000063934.89714.19"},{"key":"e_1_2_9_38_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-3046.2005.00324.x"},{"key":"e_1_2_9_39_2","first-page":"117","article-title":"Cyclosporine mono\u2010drug therapy","volume":"20","author":"Salaman J","year":"1988","journal-title":"Transplant Proc"},{"key":"e_1_2_9_40_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.TP.0000058745.02123.6F"},{"key":"e_1_2_9_41_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2005.01211.x"},{"key":"e_1_2_9_42_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.7.2592"},{"key":"e_1_2_9_43_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-05-021782"},{"key":"e_1_2_9_44_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-200201150-00019"},{"key":"e_1_2_9_45_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2004.00693.x"},{"key":"e_1_2_9_46_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-0012.2005.00342.x"}],"container-title":["Pediatric Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1399-3046.2008.00969.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1399-3046.2008.00969.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T12:44:53Z","timestamp":1696941893000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1399-3046.2008.00969.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1,6]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,2]]}},"alternative-id":["10.1111\/j.1399-3046.2008.00969.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1399-3046.2008.00969.x","archive":["Portico"],"relation":{},"ISSN":["1397-3142","1399-3046"],"issn-type":[{"value":"1397-3142","type":"print"},{"value":"1399-3046","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,1,6]]}}}